Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial
The Lancet Psychiatry
Fecha de publicación: 8 April 2019
DOI: https://doi.org/10.1016/S2215-0366(19)30047-1
Autores: Prof Simon Gilbody, DPhil., Emily Peckham, PhD., Della Bailey, MSc., Catherine Arundel, MSc., Paul Heron, MRes., Suzanne Crosland, PGDip., et al.
Background: People with severe mental illnesses such as schizophrenia are three times more likely to smoke than the wider population, contributing to widening health inequalities. Smoking remains the largest modifiable risk factor for this health inequality, but people with severe mental illness have not historically engaged with smoking cessation services. We aimed to test the effectiveness of a combined behavioural and pharmacological smoking cessation intervention targeted specifically at people with severe mental illness.
